- Home
- DX vs IMTX Comparison
DX vs IMTX Comparison
Compare DX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- IMTX
- Stock Information
- Founded
- DX 1987
- IMTX N/A
- Country
- DX United States
- IMTX Germany
- Employees
- DX N/A
- IMTX N/A
- Industry
- DX Real Estate Investment Trusts
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DX Real Estate
- IMTX Health Care
- Exchange
- DX Nasdaq
- IMTX Nasdaq
- Market Cap
- DX 984.9M
- IMTX 954.2M
- IPO Year
- DX N/A
- IMTX N/A
- Fundamental
- Price
- DX $12.56
- IMTX $6.85
- Analyst Decision
- DX Strong Buy
- IMTX Strong Buy
- Analyst Count
- DX 5
- IMTX 4
- Target Price
- DX $13.33
- IMTX $16.67
- AVG Volume (30 Days)
- DX 1.8M
- IMTX 516.6K
- Earning Date
- DX 01-27-2025
- IMTX 11-18-2024
- Dividend Yield
- DX 14.32%
- IMTX N/A
- EPS Growth
- DX 1170.16
- IMTX N/A
- EPS
- DX 1.22
- IMTX N/A
- Revenue
- DX $123,176,000.00
- IMTX $128,824,447.00
- Revenue This Year
- DX N/A
- IMTX $120.90
- Revenue Next Year
- DX $712.64
- IMTX N/A
- P/E Ratio
- DX $10.28
- IMTX N/A
- Revenue Growth
- DX 172.15
- IMTX 52.53
- 52 Week Low
- DX $11.36
- IMTX $6.68
- 52 Week High
- DX $13.13
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- DX 51.22
- IMTX 27.51
- Support Level
- DX $12.30
- IMTX $6.68
- Resistance Level
- DX $12.80
- IMTX $7.40
- Average True Range (ATR)
- DX 0.18
- IMTX 0.33
- MACD
- DX -0.02
- IMTX -0.03
- Stochastic Oscillator
- DX 48.15
- IMTX 10.43
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including residential MBS and commercial MBS.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.